State Street SPDR S&P Pharmaceuticals ETF
XPH
59 hedge funds and large institutions have $117M invested in State Street SPDR S&P Pharmaceuticals ETF in 2023 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 23 reducing their positions, and 9 closing their positions.
38% more capital invested
Capital invested by funds: $84.3M → $117M (+$32.3M)
8.8% more ownership
Funds ownership: 43.87% → 52.68% (+8.8%)
3% less funds holding
Funds holding: 61 → 59 (-2)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
52% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 23
93% less call options, than puts
Call options by funds: $86K | Put options by funds: $1.32M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$53.7M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.01M |
| 3 |
Jane Street
New York
|
+$893K |
| 4 |
FCBT
First Citizens Bank & Trust
Raleigh,
North Carolina
|
+$561K |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$527K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$8.21M |
| 2 |
Goldman Sachs
New York
|
-$5.53M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$4.9M |
| 4 |
LWM
Lionsbridge Wealth Management
Jacksonville Beach,
Florida
|
-$1.49M |
| 5 |
GSIAS
Garden State Investment Advisory Services
Red Bank,
New Jersey
|
-$737K |
XPH Hedge Fund Activity: Q2 2023 in Review
59 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q2 2023, worth a combined $117M — up 38% from $84.3M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of XPH and 7 opened new positions — a net loss of 2 holders — while 23 trimmed existing stakes and 11 added.
The largest buyer was Clal Insurance, opening a new position worth an estimated $53.7M. The largest seller was Morgan Stanley, cutting an estimated $8.21M.
- 59 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q2 2023, down from 61 in Q1 2023.
- Funds reported $117M of State Street SPDR S&P Pharmaceuticals ETF stock for Q2 2023, up 38% quarter-over-quarter.
- 7 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q2 2023 and 9 closed out, a net change of -2 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q2 2023 was Clal Insurance, an estimated $53.7M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q2 2023 was Morgan Stanley, an estimated $8.21M sold.
Based on aggregated 13F filings for Q2 2023.